Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis
Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, Yu JB. Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. Value In Health 2016, 19: 631-638. PMID: 27565280, PMCID: PMC5002308, DOI: 10.1016/j.jval.2016.02.010.Peer-Reviewed Original ResearchConceptsComponent summary scoresSF-6D scoresMental component summary scoresSurvivors of prostateYear of diagnosisPoor-prognosis cancerCancer survivorsSummary scoresCancer diagnosisCervical cancerLower mental component summary scoresLower SF-6D scoresPhysical component summary scoreCancer typesSurvivors of breastHealth-related qualityLevel of HRQoLPatient demographic characteristicsBreast cancer survivorsDecade of diagnosisDemographic characteristicsMost cancer survivorsMedical Expenditure Panel SurveyQuality of lifePoor mental healthAssessing cost-utility of predictive biomarkers in oncology: a streamlined approach
Safonov A, Wang S, Gross CP, Agarwal D, Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research And Treatment 2016, 155: 223-234. PMID: 26749360, PMCID: PMC5990969, DOI: 10.1007/s10549-016-3677-3.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness analysisPredictive biomarkersBiomarker-guided treatmentIncremental cost-effectiveness ratioHealth-related qualityTreatment costsCost-effectiveness ratioClinical outcomesClinical efficacyPrognostic biomarkerTraditional cost-effectiveness analysisBiomarker useLife yearsBiomarker valuesBiomarker prevalenceClinical literatureBiomarkersTreatmentState transition modelDecision analytic approachMedical utilityDecision analytic toolsCrizotinibHER2